October 18, 2019 Acad, Gov/Utilities Bio/Pharma/CRO

Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications

Basel, 18 October 2019 Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at... Read more

October 14, 2019 Bio/Pharma/CRO PR/Corporate

Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris

Basel, 14 October 2019 Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris 40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of patients on mycophenolate mofetil Study... Read more

September 30, 2019 Bio/Pharma/CRO PR/Corporate

Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer

Basel, 30 September 2019 Roche presents positive Phase III results for Tecentriq® (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the first positive Phase III study of a cancer immunotherapy combination in people with previously untreated advanced bladder cancer Tecentriq combination reduced the risk of disease worsening... Read more

September 30, 2019 Life Science Tools PR/Corporate

Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa

Basel, 30 September 2019 Roche to present results of first prospective trial using blood-based next generation sequencing which successfully identifies people for treatment with Alecensa Efficacy of Alecensa® (alectinib) in people identified to have ALK-positive non-small cell lung cancer using liquid biopsy is consistent with efficacy in those identified by tissue analysis in the pivotal... Read more

September 30, 2019 Acad, Gov/Utilities

FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders

Basel, 30 September 2019 FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vasculitis in children are rare and associated with severe,... Read more

September 30, 2019 Atomic Spectroscopy Clinical Research/Diagn.

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 30 September 2019 Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc. Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that Roche has extended the offering period of its previously announced tender offer to purchase all of the outstanding shares... Read more

September 28, 2019 PR/Corporate Product Launch

Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer

Basel, 28 September 2019 Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer New real-world data from the Flatiron database supports clinical benefits of Alecensa® (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival... Read more

September 27, 2019 Uncategorized

Roche's Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer

Basel, 27 September 2019 Roche’s Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data will be shared with health authorities... Read more

September 27, 2019 Atomic Spectroscopy Bio/Pharma/CRO PR/Corporate

Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma

Basel, 27 September 2019 Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic therapy The combination... Read more